chartexchange

Biohaven partners with Ono in $100m IgG degrader deal

Pharmaceutical Technology | Oct 9, 2026 4:00 AM EDT

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.

Read original article